Latest Research for Mantle Cell Lymphoma: Understanding Glofitamab with Dr. Craig Portell

Posted on: Oct 10, 2025

Play Episode

Also available on

Description

This show will not be live streamed. You can submit your questions in advance by clicking the button "Notify when available."

Join us as we unpack the latest research on glofitamab for mantle cell lymphoma (MCL). We’ll break down the study, compare glofitamab to current treatment options, and explain what this could mean for patients facing relapsed or refractory MCL.

Overview

HealthTree Resources:

Let me know your thoughts on today's episode! Share them in a comment or reach out anytime at hannah@healthtree.org.

On this episode

Hannah Loosle

Hannah joined HealthTree Foundation as the Lymphoma Education Manager in 2024. She is a Certified Health Education Specialist and is passionate about helping patients feel empowered through education and connection. Before joining HealthTree, Hannah worked in healthcare policy helping patients advocate for better care, research, and funding. Hannah enjoys baking and going to concerts in her free time.

Craig Portell, MD

Dr. Craig Portell holds a clinical faculty appointment in medicine in the Division of Hematology/Oncology at the University of Virginia. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Health. He attended medical school at Saint Louis University in St. Louis, MO, and completed internal medicine residency at Loyola University Hospital near Chicago, IL. He completed fellowship in Hematology and Medical Oncology at the Cleveland Clinic, Cleveland, OH, in 2013, where he was chief fellow from 2012-2013.

Transcript

Latest Research for Mantle Cell Lymphoma: Understanding Glofitamab with Dr. Craig Portell

Related Content